Tablet-based Patient Reported Outcome

Status Completed

Clinical Trial Summary

This study is a single arm feasibility study. Patients that have been diagnosed with carcinoma and are undergoing chemotherapy have to document chemotherapy associated side effects on a regular basis by means of a tablet-based online questionnaire. Goal of the study is to find out if patients that are undergoing chemotherapy are willing to document chemotherapy associated side effects by means of a tablet-based online questionnaire.

Clinical Trial Description

n/a

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

Antineoplastic Agents

Clinical Trial Details

NCT number	NCT01991691
Study type	Interventional
Source	University Hospital, Bonn
Contact
Status	Completed
Phase	N/A
Start date	September 2013
Completion date	December 2015

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04518852` - TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC	Phase 2
Active, not recruiting	`NCT03284255` - Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study	N/A
Recruiting	`NCT04566952` - Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer	Phase 2
Recruiting	`NCT05964101` - Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma	Phase 2
Not yet recruiting	`NCT05030077` - Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma	Phase 2
Recruiting	`NCT04556071` - Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	Phase 2
Recruiting	`NCT03606369` - Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.	Phase 2/Phase 3
Completed	`NCT03403777` - Avelumab in Refractory Testicular Germ Cell Cancer.	Phase 2
Recruiting	`NCT05814224` - Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA	N/A
Active, not recruiting	`NCT04309084` - Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma	Phase 1
Active, not recruiting	`NCT05241873` - (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations	Phase 1/Phase 2
Completed	`NCT00541801` - Acoustic Cardiographic Assessment of Heart Function in Comparison to Doppler-echocardiography	N/A
Active, not recruiting	`NCT04862780` - (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC	Phase 1/Phase 2
Recruiting	`NCT04922047` - Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)	Phase 1/Phase 2
Completed	`NCT01316458` - Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy	Phase 2
Not yet recruiting	`NCT04807166` - Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer	Phase 2
Completed	`NCT04002284` - Anlotinib in Metastatic HER2 Negative Breast Cancer	Phase 2
Not yet recruiting	`NCT04962958` - Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery	Phase 2
Active, not recruiting	`NCT02468245` - Does a Nursing Intervention Improve Adherence to Oral Chemotherapies in the Outpatient Cancer Treatment Setting?	N/A
Terminated	`NCT05153408` - (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC	Phase 1